
WHAT IS CLAIMED IS:

1. A nanoparticle comprising


(i) a lipid component comprising a compound having the structure



(Compound A), and

(ii) a modified RNA comprising any one of SEQ ID NOs: 1 and 3-5, encoding a VEGF-A polypeptide of SEQ ID NO: 2.

2. A pharmaceutical composition comprising

(a) at least one nanoparticle comprising (i) a lipid component comprising a compound having the structure 
(Compound A), and (ii) a modified RNA comprising any one of SEQ ID NOs: 1 and 3-5, encoding a VEGF-A polypeptide of SEQ ID NO: 2; and

(b) a pharmaceutically acceptable excipient.

3. The nanoparticle of claim 1, or the pharmaceutical composition of claim 2, wherein the lipid component further comprises a phospholipid, a structural lipid, and/or a PEG lipid; wherein the phospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-gly cero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine,1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-

glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof;

the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof; and/or

the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

4. The nanoparticle of claim 1, or the pharmaceutical composition of claim 2, wherein the lipid component further comprises a phospholipid that is DSPC, a structural lipid that is cholesterol, and/or a PEG lipid that is PEG-DMG.

5. The nanoparticle according to any one of claims 1, 3 and 4, or the pharmaceutical composition according to any one of claims 2-4, wherein the N:P ratio is from about 2:1 to about 30:1, optionally about 5.67:1 or about 3:1.

6. The nanoparticle according to any one of claims 1 and 3-5, or the pharmaceutical composition according to any one of claims 2-5, wherein the wt/wt ratio of the lipid component to the modified RNA is from about 10:1 to about 100:1, optionally about 20:1 or about 10:1.

7. The nanoparticle according to any one of claims 1 and 3-5, or the pharmaceutical composition according to any one of claims 2-6, wherein the nanoparticle has a mean diameter from about 50nm to about 100nm.

8. The pharmaceutical composition according to any one of claims 2-7, wherein when administered to a mammalian tissue or a subject, the pharmaceutical composition results in

(a) a maximum observed plasma and/or tissue concentration, C_{max}, of the VEGF-A polypeptide of SEQ ID NO: 2 up to about 450 pg/ml plasma or pg/mg tissue; or

(b) a plasma and/or tissue total area under the concentration curve, AUC_{0-t}, of the VEGF-A polypeptide of SEQ ID NO: 2 up to about 5,500 pg*h/ml plasma or pg*h/mg tissue.

9. The pharmaceutical composition according to any one of claims 2-7, wherein when administered to a mammalian tissue or a subject, the pharmaceutical composition results in

(a) the production of more than about 400 pg/mg tissue of the VEGF-A polypeptide of SEQ ID NO: 2 within 8 hours; or

(b) the production of more than about 1 pg/mg tissue of the VEGF-A polypeptide of SEQ ID NO: 2 for up to 6 days.

10. The pharmaceutical composition according to any one of claims 2-9, wherein the pharmaceutically acceptable excipient is chosen from a solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, polymer, peptide, protein, cell, hyaluronidase, and mixtures thereof.

11. The nanoparticle according to any one of claims 1 and 3-7 or a pharmaceutical composition according to any one of claims 2-10 for use in promoting and/or improving wound healing in a subject.

12. The nanoparticle or pharmaceutical composition for use according to claim 11, wherein the nanoparticle or the pharmaceutical composition is to be administered intradermally.

13. The nanoparticle or pharmaceutical composition for use according to claim 11, wherein the concentration of the modified RNA is from about 0.01 mg/kg to about 10 mg/kg.

14. The nanoparticle or pharmaceutical composition for use according to claim 11, wherein the subject suffers from diabetes.

15. The nanoparticle or pharmaceutical composition for use according to claim 11, wherein the wound is a surgical wound, a burn, an abrasive wound, a skin biopsy site, a chronic wound, an injury (e.g., a traumatic injury wound), a graft wound, a diabetic wound, a diabetic ulcer (e.g., diabetic foot ulcer), a pressure ulcer, bed sore, and combinations thereof.